FlowAid Medical Technologies Corp.

FlowAid Medical Technologies Corp. is a medical device company with one chief objective: to address the complications arising from inadequate blood flow. Our vision is to be the leaders in treating circulatory disorders of the extremities with new innovative cutting edge technologies. Our goal is to improve the quality of patient care and vascular health care delivery through the development of non-invasive medical devices and procedures for increasing blood flow and circulatory enhancement. We accomplish this through continuous refinement of existing products and through the development of new technologies that can reduce risk, trauma, cost, procedure time and the need for aftercare. The European Community CE mark approval was granted for the FA100 SCCD Sequential Contraction Compression Device on July 7, 2016. The Health Canada MDL License No.: 97539 was granted just a month later on August 18, 2016. U.S. Food and Drug Administration FDA clearance K162987 was granted for the FA100 SCCD (Sequential Continuous Contraction Device) on February 14, 2017.